Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab in Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
2024-519930-22-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Sep 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of mosunetuzumab in systemic lupus erythematosus (SLE) and lupus nephritis (LN) (2 cohorts), sponsored by Roche. Primary endpoint: Drug-free remission by Week 76. Planned start Sep 2025; status: authorised.
02
Drugs
mosunetuzumab
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on 2024-519930-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519930-22-00.